Klinisch orientierter Schwerpunkt
FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz
Weide, R.; Feiten, S.; Wassmann, C. et al.
Metastatic breast cancer: survival improvement in routine care 1995-2022ONCOLOGY RESEARCH AND TREATMENT. Bd. 46. 2023 S. 28-28
Kriegsmann, Katharina; Bittrich, Max; Sauer, Sandra et al.
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB StudyTRANSFUSION MEDICINE AND HEMOTHERAPY. Bd. 50. H. 5. 2023 S. 403-416
Haber, Philipp K.; Castet, Florian; Torres-Martin, Miguel et al.
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular CarcinomaGASTROENTEROLOGY. Bd. 164. H. 1. 2023
Greco, Raffaella; Hoogenboom, Jorinde D.; Bonneville, Edouard F. et al.
Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working PartyBONE MARROW TRANSPLANTATION. 2023
Harbeck, Nadia; Wrobel, Denise; Zaiss, Matthias et al.
Neratinib as extended adjuvant treatment of HER2-positive/HR-positive early breast cancer patients in Germany, Austria and Switzerland: interim results of the prospective, observational ELEANOR studyBREAST CARE. 2023
Ugurel, Selma; Schmidberger, Heinz
New trends in melanoma From adjuvant therapy in stage II to novel treatment strategies with ImmTACsONKOLOGIE. Bd. 29. H. 8. 2023 S. 656-659
Lupo, Philip J.; Chambers, Tiffany M.; Mueller, Beth A. et al.
Nonchromosomal birth defects and risk of childhood acute leukemia: An assessment in 15?000 leukemia cases and 46?000 controls from the Childhood Cancer and Leukemia International ConsortiumINTERNATIONAL JOURNAL OF CANCER. 2023
Janni, Wolfgang; Fehm, Tanja; Muller, Volkmar et al.
Omission of chemotherapy in the treatment of HER2-positive and hormone-receptor positive metastatic breast cancer - interim results from the randomized phase 3 DETECT V trialCANCER RESEARCH. Bd. 83. H. 5. 2023
Hasenburg, Annette; Blohmer, Jens-Uwe; Janni, Wolfgang et al.
Oncology - Dose-intensive training in gynecological oncology - AGO State of the Art 2023GEBURTSHILFE UND FRAUENHEILKUNDE. Bd. 83. H. 10. 2023 S. 1179-1183
Pfisterer, Jacobus; Joly, Florence; Kristensen, Gunnar et al.
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III TrialJOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 4. 2023 S. 893-+